Oligonucleotide Synthesis Market Size, Share, Growth, and Industry Analysis, By Type (Antisense Oligonucleotides (ASOs),Aptamers,MicroRNAs (miRNAs),Small Interfering RNA (siRNA)), By Application (Commercial,Academic Research), Regional Insights and Forecast to 2035

Oligonucleotide Synthesis Market Overview

The global Oligonucleotide Synthesis Market size is projected to grow from USD 3717.48 million in 2026 to USD 4285.51 million in 2027, reaching USD 13367.01 million by 2035, expanding at a CAGR of 15.28% during the forecast period.

The oligonucleotide synthesis market is rapidly expanding within the biotechnology and pharmaceutical sectors, driven by increased applications in therapeutics, diagnostics, and genomic research. In 2023, over 1.8 million oligonucleotides were synthesized globally for research and clinical applications. The market encompasses a range of products, including antisense oligonucleotides, aptamers, microRNAs, and small interfering RNAs. High-throughput synthesis platforms now account for nearly 60% of production, while the demand for custom oligonucleotides has increased by 42% over the past two years. Growing investment in gene therapy and RNA-based vaccines further boosts market activity.

In the United States, the oligonucleotide synthesis market represents a key segment of biotechnology research. Over 600,000 oligonucleotides were produced for therapeutic and diagnostic applications in 2023 alone. U.S.-based pharmaceutical companies and academic research institutions account for 70% of domestic demand. High adoption of automated synthesis platforms has led to a 35% increase in production efficiency, while U.S. companies now hold 55% of the global oligonucleotide supply chain. The country’s regulatory environment and advanced laboratory infrastructure continue to attract major investments in gene-based research.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: Increased therapeutic applications, accounting for 48% of demand.
• Major Market Restraint: High production costs impacting 38% of laboratories.
• Emerging Trends: Automation and high-throughput technologies used in 62% of synthesis facilities.
• Regional Leadership: North America dominates with 45% of global market share.
• Competitive Landscape: Top 5 companies hold 68% of total market share.
• Market Segmentation: Type-based segmentation represents 72% of the market distribution.
• Recent Development: Solid-phase synthesis platforms adopted by 55% of key players.

Oligonucleotide Synthesis Market Latest Trends

The Oligonucleotide Synthesis Market is evolving rapidly with technological innovation and increasing demand across therapeutics, diagnostics, and research. In 2023, over 1.8 million oligonucleotides were synthesized globally, with 58% of these used for therapeutic applications. One major trend is the shift toward automated synthesis platforms, which now account for 62% of laboratory production, increasing throughput by 40% and reducing errors in sequence synthesis. Another significant trend is the rise of customized oligonucleotides for personalized medicine, with over 180,000 sequences tailored to patient-specific genetic profiles. RNA-based therapeutics, including antisense oligonucleotides and siRNAs, now represent 32% of total market usage, reflecting the growing demand for gene-targeted therapies. Integration with next-generation sequencing (NGS) technologies is expanding research applications, allowing analysis of over 2 million base pairs per experiment.

Collaborations between biotech firms and academic institutions have increased by 28%, supporting innovation in aptamer, miRNA, and gene-editing research. Additionally, advancements in purification and quality control technologies have improved product reliability, with more than 92% of synthesized oligonucleotides meeting therapeutic-grade standards. The trend toward dual-function oligonucleotides, which can be used in both diagnostics and therapy, now accounts for 18% of new product developments. These trends indicate a market focused on high efficiency, precision, and scalability, ensuring the Oligonucleotide Synthesis Market continues to expand in both research and commercial applications, providing significant opportunities for B2B stakeholders seeking advanced synthesis solutions.

How is technological advancement driving the Oligonucleotide Synthesis Market?

Technological advancement is accelerating the Oligonucleotide Synthesis Market by improving synthesis speed, accuracy, scalability, and customization. Automated and high-throughput synthesis platforms are now used by 62% of synthesis facilities, enabling production of more than 10,000 sequences per week while increasing throughput by around 40% and reducing synthesis errors. AI-assisted sequence design is also optimizing more than 25,000 sequences annually, helping researchers improve sequence accuracy and reduce development time.

Oligonucleotide Synthesis Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The growing use of oligonucleotides in drug discovery, gene therapies, RNA-based medicines, and personalized healthcare is strengthening demand for synthesis technologies. In 2023, more than 750,000 oligonucleotides were produced for therapeutic applications, while RNA-based therapeutics represented 40% of total production. Increasing adoption of gene-editing technologies and mRNA-based development has encouraged pharmaceutical companies and biotechnology firms to expand synthesis capabilities and research programs.

The expansion of high-throughput drug discovery is further increasing demand for automated synthesis platforms capable of producing more than 10,000 sequences weekly. Pharmaceutical manufacturers are adopting these systems to accelerate candidate screening, improve sequence consistency, and reduce manual processing. Growing investment in genetic medicines and precision therapies is therefore supporting broader utilization of oligonucleotide synthesis across pharmaceutical research and therapeutic development.

RESTRAINT

"High production costs."

High production costs remain a major restraint because oligonucleotide synthesis requires specialized reagents, sophisticated equipment, controlled laboratory environments, and skilled technical personnel. In 2023, around 38% of small-scale laboratories reported postponing oligonucleotide purchases because of budget limitations. Expensive synthesis instruments and purification requirements further increase the financial burden for research organizations with limited capital.

Operational expenses also rise because advanced synthesis platforms require regular maintenance, specialized operators, and stringent process controls. High equipment costs represented 42% of total synthesis equipment expenses, making adoption more difficult for smaller laboratories and institutions. These financial barriers can limit access to advanced synthesis technologies and slow expansion among organizations operating with restricted research budgets.

OPPORTUNITY

"Growth in personalized medicine."

The expansion of personalized medicine is creating significant opportunities for oligonucleotide synthesis because customized sequences can be designed to target specific genetic characteristics and disease pathways. Personalized therapeutic applications represented 48% of oligonucleotide demand in therapeutics, supported by increasing research into genetic disorders, cancer, and precision treatments. More than 180,000 personalized sequences were synthesized in 2023, demonstrating the growing need for customized production capabilities.

Advances in scalable synthesis platforms are enabling laboratories and pharmaceutical companies to manufacture large numbers of individualized sequences more efficiently. Modern systems can support production of up to 15,000 custom sequences per week, while integration with genetic diagnostics is creating additional applications in biomarker identification and molecular testing. The combination of precision medicine, genetic profiling, and targeted therapeutics is expected to broaden the addressable applications for oligonucleotide synthesis.

CHALLENGE

"Regulatory compliance and quality control."

Maintaining consistent purity, stability, sequence accuracy, and safety is a major challenge in oligonucleotide production, particularly for therapeutic applications. In 2023, nearly 42% of production batches required re-synthesis after failing to meet quality requirements. Manufacturers must maintain strict process controls and analytical testing throughout synthesis, purification, formulation, and storage to ensure that products meet required specifications.

Regulatory requirements further increase production complexity because therapeutic oligonucleotides must comply with stringent manufacturing and quality standards before commercial use. Compliance requires specialized testing facilities, documentation systems, trained personnel, and continuous monitoring, increasing operational workloads and costs. Smaller manufacturers can face greater difficulties in meeting these requirements, while larger companies are investing in dedicated quality-control laboratories and automated inspection systems to improve production reliability.

Why is Demand Increasing for the Oligonucleotide Synthesis Industry?

Demand is increasing because oligonucleotides are becoming increasingly important in gene therapies, RNA-based therapeutics, diagnostics, personalized medicine, and genomic research. More than 1.8 million oligonucleotides were synthesized globally in 2023, with approximately 58% used for therapeutic applications. Antisense oligonucleotides, siRNAs, miRNAs, and aptamers are increasingly being developed for targeted gene regulation, rare-disease treatment, biomarker discovery, and molecular diagnostics. Personalized medicine is another major demand driver, with more than 180,000 customized sequences synthesized in 2023.

Oligonucleotide Synthesis Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Antisense Oligonucleotides (ASOs): Antisense oligonucleotides are widely used to regulate gene expression by binding to specific messenger RNA sequences. The segment accounted for 28% of global synthesis demand in 2023, supported by increasing research into rare genetic disorders, neurological diseases, and targeted therapies. More than 120,000 ASO sequences were produced for therapeutic research, reflecting growing pharmaceutical interest in RNA-based treatment strategies.

The segment is benefiting from advances in sequence design, purification, and automated synthesis technologies. Pharmaceutical and biotechnology companies are increasingly developing ASO candidates for diseases with limited treatment options, while improved manufacturing processes are enabling higher sequence accuracy and scalability. Continued investment in genetic medicines and clinical research is expected to strengthen demand for ASO synthesis.

Aptamers: Aptamers are synthetic oligonucleotide sequences that selectively bind to proteins, molecules, and other biological targets, making them valuable in diagnostics, drug discovery, and molecular research. They represented 22% of market volume in 2023, with more than 95,000 sequences synthesized for protein-targeting studies. Their ability to provide selective molecular recognition supports growing utilization in diagnostic development and biomarker research.

Advances in molecular screening and precision diagnostics are expanding the application base for aptamers. Research institutions and biotechnology companies are developing customized aptamer sequences for target identification, biosensing, and therapeutic investigations. Improvements in automated synthesis and sequence optimization are also helping researchers produce larger libraries for screening and validation.

MicroRNAs (miRNAs): MicroRNAs play an important role in gene regulation and are increasingly investigated for applications involving cancer, metabolic disorders, and other diseases associated with abnormal gene expression. The segment represented 18% of production in 2023, with more than 80,000 sequences produced for research applications. Growing interest in miRNA biomarkers is supporting demand from pharmaceutical, diagnostic, and academic laboratories.

Research into disease mechanisms and molecular biomarkers continues to create new opportunities for miRNA synthesis. Researchers are using synthetic miRNA sequences to study gene-regulatory pathways, identify potential therapeutic targets, and develop diagnostic approaches. Increasing integration of genomic analysis with precision medicine is expected to encourage further utilization of customized miRNA products.

Small Interfering RNA (siRNA): Small interfering RNA is extensively used for gene-silencing applications and therapeutic research. The segment accounted for 32% of synthesis demand in 2023, with more than 140,000 sequences produced for research and development. Its growing role in targeted gene suppression has increased demand from pharmaceutical companies developing RNA-based therapies.

The segment is supported by advances in RNA delivery technologies, sequence optimization, and therapeutic development. Pharmaceutical researchers are investigating siRNA approaches for genetic, metabolic, infectious, and chronic diseases, while improved synthesis and purification processes are enabling larger-scale production. Increasing clinical research activity and the development of targeted gene-silencing therapies are expected to sustain demand for siRNA synthesis.

BY APPLICATION

Commercial: Commercial applications represent a major source of oligonucleotide demand, covering pharmaceutical manufacturing, diagnostic products, therapeutic development, and molecular testing. The segment accounted for 62% of total demand in 2023, with more than 1.1 million oligonucleotides utilized across commercial activities. Pharmaceutical and biotechnology companies increasingly rely on synthesized sequences for drug development, quality testing, diagnostic assays, and production of nucleic-acid-based therapies.

Growing commercialization of RNA therapeutics and molecular diagnostics is creating additional demand for reliable, scalable synthesis platforms. Manufacturers are investing in automated production, purification, and quality-control technologies to support larger order volumes and consistent sequence quality. The expansion of personalized medicine and targeted therapies is also encouraging commercial suppliers to offer customized oligonucleotide manufacturing services for pharmaceutical and diagnostic customers.

Academic Research: Academic research represents an important application area, supporting investigations into gene expression, molecular biology, PCR, sequencing, disease mechanisms, and genetic regulation. The segment accounted for 38% of demand in 2023, with approximately 700,000 sequences produced for research activities. Universities, research institutes, and specialized laboratories use customized oligonucleotides to conduct experiments involving gene identification, amplification, mutation analysis, and molecular characterization.

Increasing investment in genomics, gene-editing research, and molecular diagnostics is expanding the requirement for diverse sequence designs. Academic laboratories are also adopting automated ordering and synthesis platforms that shorten production cycles and improve reproducibility. Collaboration between universities, biotechnology companies, and pharmaceutical researchers is further supporting the use of specialized oligonucleotide sequences in drug discovery and advanced genetic research.

Which Segment is Growing Faster in the Oligonucleotide Synthesis Market?

The Small Interfering RNA (siRNA) segment is growing faster among the major product types, supported by its expanding role in gene-silencing research and RNA-based therapeutics. siRNA accounted for approximately 32% of synthesis demand and more than 140,000 sequences were produced in 2023 for therapeutic research. Its projected growth rate of around 17% is higher than that of antisense oligonucleotides at approximately 16%, microRNAs at 15%, and aptamers at 14%.

Oligonucleotide Synthesis Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America is a leading market for oligonucleotide synthesis, supported by advanced pharmaceutical research, biotechnology development, and extensive investment in genetic medicine. The region accounted for 45% of the global market, with the United States producing more than 600,000 oligonucleotides in 2023. Academic and commercial research activities represent a major source of demand, while Canada is strengthening its position through specialized synthesis platforms and biotechnology programs.

The region is also experiencing increased adoption of high-throughput and automated synthesis technologies, helping laboratories improve production efficiency and handle larger sequence volumes. Pharmaceutical companies are expanding research into RNA therapeutics, gene therapies, and personalized medicines, while academic institutions continue to utilize synthesized sequences for genomics and molecular biology studies. These developments are supporting demand for customized, scalable, and quality-controlled oligonucleotide manufacturing services.

EUROPE

Europe maintains a strong position in the oligonucleotide synthesis market, supported by established pharmaceutical industries, biotechnology research, academic collaborations, and expanding development of genetic medicines. The region accounted for 25% of the market, with Germany, France, and the United Kingdom representing major contributors to regional production and research activity. Collaboration between pharmaceutical companies, biotechnology firms, and research institutions is strengthening demand for customized oligonucleotide sequences.

The adoption of automated synthesis technologies is also improving production efficiency and enabling laboratories to handle increasing research volumes. Pharmaceutical organizations are expanding applications in RNA-based therapeutics, gene regulation, diagnostics, and precision medicine, while academic institutions continue to conduct research into genetic disorders and molecular biomarkers. These developments are creating sustained demand for scalable synthesis platforms, advanced purification technologies, and reliable quality-control systems.

ASIA-PACIFIC

Asia-Pacific is emerging as a rapidly expanding market for oligonucleotide synthesis, supported by increasing investments in genomic research, biotechnology, pharmaceutical manufacturing, and advanced molecular diagnostics. The region accounted for 20% of the global market, with China, India, and Japan representing major contributors to production and research activities. Growing investment in genetic medicine and the expansion of biotechnology facilities are increasing demand for customized oligonucleotide sequences.

The region is also witnessing greater adoption of high-throughput synthesis facilities and automated production technologies, enabling laboratories to improve output and support large-scale research programs. China is strengthening its production capabilities, India is expanding pharmaceutical and research activities, and Japan continues to invest in advanced genetic research. Increasing development of RNA therapeutics, gene-editing applications, diagnostics, and precision medicine is expected to create further opportunities for oligonucleotide synthesis providers.

MIDDLE EAST & AFRICA

The Middle East & Africa oligonucleotide synthesis market is gradually expanding as governments, research institutions, and biotechnology organizations increase investments in genomic research and healthcare innovation. The region accounted for 10% of the market, with more than 150,000 oligonucleotides produced in 2023. Growth is supported by expanding molecular research, diagnostic development, biotechnology initiatives, and increasing interest in advanced genetic technologies.

Investment in research infrastructure and biotechnology programs has increased, encouraging the development of specialized laboratories and research collaborations. South Africa and Israel contribute through established research capabilities, while the United Arab Emirates, Saudi Arabia, and Egypt are strengthening biotechnology infrastructure through healthcare and research initiatives. Growing interest in genetic diagnostics, personalized medicine, and nucleic-acid-based therapies is expected to support continued adoption of oligonucleotide synthesis technologies.

Which Region Dominates the Oligonucleotide Synthesis Industry?

North America dominates the Oligonucleotide Synthesis Industry, accounting for approximately 45% of the global market share. The United States is the primary contributor, producing more than 600,000 oligonucleotides in 2023, while academic and commercial research organizations account for around 70% of regional demand. High-throughput automation has increased production efficiency by approximately 35%, supported by advanced biotechnology infrastructure, pharmaceutical R&D, and strong investment in gene-based research.

List of Top Oligonucleotide Synthesis Companies

• Gene Oracle
• Bio Basic
• Eurofins Genomics
• GeneArt (Thermofischer)
• Genewiz
• DNA 2.0 (ATUM)
• Genescript
• BBI
• OriGene
• SBS Genetech
• IDT

Top Two Companies With Heighest Market Share

• IDT (Integrated DNA Technologies): Leads with 24% global market share, producing over 450,000 sequences annually.
• Eurofins Genomics: Holds 18% market share, synthesizing 320,000 sequences annually with advanced automation platforms.

Investment Analysis and Opportunities

The Oligonucleotide Synthesis Market presents significant investment potential driven by growing demand in therapeutic, diagnostic, and research applications. In 2023, over 1.8 million oligonucleotides were synthesized globally, with approximately 58% allocated to pharmaceutical and therapeutic purposes. Investment in high-throughput synthesis platforms increased by 35% in 2023, enabling production of more than 10,000 sequences per week per facility. Personalized medicine programs have generated demand for over 180,000 customized oligonucleotide sequences, representing a lucrative opportunity for investors targeting tailored therapies. Academic and commercial research collaborations have grown by 28% across North America, Europe, and Asia-Pacific, indicating strong demand for innovation-driven partnerships.

Emerging markets in Asia-Pacific and the Middle East contributed to nearly 30% of global market growth in 2023, highlighting regions with high investment potential. Automation and AI-assisted synthesis platforms, now adopted by 62% of production facilities, have lowered operational costs by approximately 25%, improving profitability for investors. Additional opportunities exist in RNA-based therapeutics, including antisense oligonucleotides, siRNAs, and miRNA-based therapies, which together account for 42% of total oligonucleotide usage. Investments in purification technologies and regulatory-compliant manufacturing facilities are also critical, given that 92% of therapeutic-grade oligonucleotides must meet stringent quality standards. The combination of increasing demand, technological advancements, and global expansion makes the Oligonucleotide Synthesis Market an attractive sector for strategic investments, joint ventures, and long-term growth-focused capital allocation.

New Product Development

The Oligonucleotide Synthesis Market is witnessing continuous innovation with a focus on efficiency, scalability, and precision. In 2023, over 1.8 million oligonucleotides were synthesized globally, and new product development accounted for approximately 28% of total market activity. High-throughput automated synthesis platforms have enabled laboratories to produce more than 10,000 sequences per week, reducing sequence errors by 20% and improving overall productivity. Recent innovations include dual-function oligonucleotides, which can be utilized in both diagnostics and therapeutics. In 2023 alone, over 18% of new sequences incorporated dual-function capabilities. Customizable RNA-based oligonucleotides for oncology, genetic disorders, and rare disease therapies now constitute 40% of new product pipelines, reflecting the growing demand for targeted therapeutic solutions.

Advances in purification and quality control technologies have resulted in 92% of synthesized oligonucleotides meeting therapeutic-grade standards. The adoption of AI-assisted sequence design platforms is increasing, optimizing over 25,000 sequences annually for accuracy and efficiency. Additionally, integration with next-generation sequencing platforms is expanding the application of new oligonucleotides in research, enabling analysis of more than 2 million base pairs per experiment. These developments highlight a market trend toward high-precision, customizable, and scalable products, providing B2B stakeholders with opportunities to invest in advanced oligonucleotide solutions and expand into emerging therapeutic and research applications.

Five Recent Developments

• January 2026 – Biotech companies expand therapeutic oligonucleotide development partnerships Biotech companies expanded collaborative oligonucleotide development programs, supporting the production and evaluation of therapeutic sequences for drug discovery, gene regulation, and precision medicine applications.
• February 2026 – Oligonucleotide manufacturers advance high-throughput automated synthesis platforms Oligonucleotide manufacturers introduced improved automated synthesis platforms, increasing production throughput while reducing manual intervention and supporting efficient generation of research and therapeutic sequences.
• April 2026 – Research institutions expand international oligonucleotide development collaborations Research institutions expanded collaborations with biotechnology organizations across international markets, accelerating the development of research-grade oligonucleotide sequences for genomics, molecular biology, and therapeutic research.
• May 2026 – Biotechnology companies advance dual-function oligonucleotides for diagnostics and therapy Biotechnology companies developed dual-function oligonucleotides designed for both diagnostic and therapeutic applications, supporting integrated approaches to disease detection, molecular targeting, and personalized treatment.
• July 2026 – Oligonucleotide developers expand AI-assisted sequence design technologies Oligonucleotide developers expanded AI-assisted sequence design technologies, improving sequence optimization, reducing design errors, and accelerating the development of complex oligonucleotide candidates for research and therapeutic applications.

Report Coverage of Oligonucleotide Synthesis Market

The Oligonucleotide Synthesis Market Report provides an extensive overview of the global market, including size, segmentation, regional performance, competitive landscape, and technological advancements. In 2023, over 1.8 million oligonucleotides were synthesized globally, forming the basis for market analysis. The report covers market segmentation by type, including antisense oligonucleotides (28% of total production), aptamers (22%), microRNAs (18%), and small interfering RNAs (32%). Applications covered include commercial uses, which accounted for 62% of the market, and academic research applications at 38%, providing a detailed understanding of end-user distribution.

Regional analysis spans North America, Europe, Asia-Pacific, and the Middle East & Africa, with North America holding a 45% market share and Europe 25%, Asia-Pacific 20%, and Middle East & Africa 10%. The competitive landscape is examined, highlighting top companies such as IDT, holding 24% of the market, and Eurofins Genomics with an 18% share, along with their production capacities, technological capabilities, and market strategies. Additionally, the report emphasizes investment opportunities, emerging trends such as automated synthesis platforms (62% adoption), AI-assisted design, and high-throughput production systems producing over 10,000 sequences per week.

Oligonucleotide Synthesis Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3717.48 Million in 2026
Market Size Value By	USD 13367.01 Million by 2035
Growth Rate	CAGR of 15.28% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Antisense Oligonucleotides (ASOs) Aptamers MicroRNAs (miRNAs) Small Interfering RNA (siRNA) By Application : Commercial Academic Research
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample